MLTX

47.63

2.65% 1.23

Dopo l'orario di chiusura: 47.63

Moonlake Immunotherapeutics (MLTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MLTX Giù? Forum Previsione

Precedente Chiudi:

$46.40

Aprire:

$47.22

Volume 24 ore:

228.96K

Relative Volume:

0.75

Capitalizzazione di mercato:

$3.00B

Reddito:

Utile/perdita netta:

$-54.80M

Rapporto P/E:

-40.74

EPS:

-1.1692

Flusso di cassa netto:

$-64.65M

1 W Prestazione:

-1.16%

1M Prestazione:

-13.84%

6M Prestazione:

+5.24%

1 anno Prestazione:

-7.12%

Intervallo 1D:

$45.91

$48.20

Intervallo di 1 settimana:

$45.24

$48.20

Portata 52W:

$35.11

$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Nome

Moonlake Immunotherapeutics

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

41 41 510 8022

Indirizzo

DORFSTRASSE 29, ZUG

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

MLTX's Discussions on Twitter

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-08	Iniziato	Citigroup	Buy
2023-11-02	Iniziato	Stifel	Buy
2023-09-14	Downgrade	Bryan Garnier	Buy → Neutral
2023-08-31	Iniziato	Needham	Buy
2023-06-15	Iniziato	Barclays	Equal Weight
2023-05-01	Iniziato	Guggenheim	Buy
2023-03-22	Iniziato	Wedbush	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2023-02-14	Iniziato	Cantor Fitzgerald	Overweight
2023-02-02	Iniziato	Bryan Garnier	Buy
2022-11-11	Iniziato	Jefferies	Buy
2022-08-25	Iniziato	SVB Leerink	Outperform
2022-07-21	Iniziato	H.C. Wainwright	Buy
2022-07-07	Iniziato	Cowen	Outperform

Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

08:39 AM

Wedbush Reiterates Outperform Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

08:39 AM

08:08 AM

14,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by AlphaCentric Advisors LLC - MarketBeat

08:08 AM

Nov 04, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 04, 2024

Nov 03, 2024

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Nov 03, 2024

Nov 02, 2024

Congress Asset Management Co. Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 02, 2024

Oct 30, 2024

MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq

Oct 30, 2024

Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat

Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Oct 29, 2024

Oct 26, 2024

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN

Oct 26, 2024

Oct 25, 2024

I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet

Oct 25, 2024

Oct 24, 2024

This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St

Oct 24, 2024

Oct 23, 2024

(MLTX) Proactive Strategies - Stock Traders Daily

Oct 23, 2024

Oct 17, 2024

HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Oct 17, 2024

Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria

Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India

Oct 16, 2024

Oct 15, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC Wainwright - MarketBeat

Oct 15, 2024

Oct 13, 2024

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha

Oct 13, 2024

Oct 12, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Oct 12, 2024

Oct 10, 2024